Atp13A2 Loss Of Function-Driven Polyamine Dysregulation Induces SAM Depletion And Epigenetic Astrocyte Toxicity

Researchers discovered that the malfunction of a protein called ATP13A2 in brain support cells, known as astrocytes, leads to an imbalance of essential molecules, depletes a critical cellular compound, and alters gene regulation, ultimately causing inflammation and the death of dopamine-producing neurons, which are key to Parkinson’s disease.

Our brains are incredibly complex, and understanding how diseases like Parkinson’s develop is crucial for finding new treatments. Recent research sheds light on a fascinating pathway involved in neurodegeneration, particularly in early-onset Parkinson’s disease.

At the heart of this discovery is a protein called ATP13A2. When this protein doesn’t function correctly, it causes problems within astrocytes, which are star-shaped cells that support neurons in the brain. Normally, ATP13A2 helps manage small molecules called polyamines, which are vital for cell growth and function. However, when ATP13A2 is faulty, polyamines get trapped in the cell’s recycling centers, called lysosomes, instead of being available where they’re needed in the main part of the cell.

This imbalance triggers the astrocytes to try and make more polyamines, a process called de novo polyamine biosynthesis. This compensatory effort, however, has an unintended consequence: it diverts a crucial molecule known as S-adenosyl methionine (SAM). SAM is essential for “epigenetic” processes, which are like switches that turn genes on or off without changing the underlying DNA sequence. Specifically, SAM is needed for modifying DNA and proteins called histones, which package our DNA.

With SAM depleted, these epigenetic modifications go awry, leading to changes in how tightly DNA is packed, making certain genes more accessible. This “epigenetic reprogramming” transforms astrocytes into a harmful, neuroinflammatory state. In this state, they release toxic signaling molecules that directly contribute to the death of dopamine-producing neurons—the very neurons lost in Parkinson’s disease.

Crucially, the study found that by genetically or pharmacologically blocking the use of SAM in polyamine production, this harmful epigenetic reprogramming in astrocytes could be prevented, leading to the survival of dopamine-producing neurons. These findings highlight a direct link between how cells handle polyamines, changes in gene regulation, and brain inflammation, opening up exciting new avenues for developing therapies for Parkinson’s disease.

---

Source: link to paper